BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 19932542)

  • 21. Primary FSGS in Nephrotic Adults: Clinical Profile, Response to Immunosuppression and Outcome.
    Bagchi S; Agarwal S; Kalaivani M; Bhowmik D; Singh G; Mahajan S; Dinda A
    Nephron; 2016; 132(2):81-5. PubMed ID: 26799973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis.
    Fernandez-Fresnedo G; Segarra A; González E; Alexandru S; Delgado R; Ramos N; Egido J; Praga M;
    Clin J Am Soc Nephrol; 2009 Aug; 4(8):1317-23. PubMed ID: 19578004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel therapies for FSGS: preclinical and clinical studies.
    Malaga-Dieguez L; Bouhassira D; Gipson D; Trachtman H
    Adv Chronic Kidney Dis; 2015 Mar; 22(2):e1-6. PubMed ID: 25704355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adiponectin in children and young adults with focal segmental glomerulosclerosis.
    Sethna CB; Boone V; Kwok J; Jun D; Trachtman H
    Pediatr Nephrol; 2015 Nov; 30(11):1977-85. PubMed ID: 26115618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group.
    Cattran DC; Appel GB; Hebert LA; Hunsicker LG; Pohl MA; Hoy WE; Maxwell DR; Kunis CL
    Kidney Int; 1999 Dec; 56(6):2220-6. PubMed ID: 10594798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.
    Trachtman H; Nelson P; Adler S; Campbell KN; Chaudhuri A; Derebail VK; Gambaro G; Gesualdo L; Gipson DS; Hogan J; Lieberman K; Marder B; Meyers KE; Mustafa E; Radhakrishnan J; Srivastava T; Stepanians M; Tesar V; Zhdanova O; Komers R;
    J Am Soc Nephrol; 2018 Nov; 29(11):2745-2754. PubMed ID: 30361325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis.
    Harita Y; Ishizuka K; Tanego A; Sugawara N; Chikamoto H; Akioka Y; Tsurumi H; Miura K; Gotoh Y; Tsujita M; Yamamoto T; Horike K; Takeda A; Oka A; Igarashi T; Hattori M
    Pediatr Nephrol; 2014 Sep; 29(9):1553-60. PubMed ID: 24705794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab for Recurrence of Primary Focal Segmental Glomerulosclerosis After Kidney Transplantation: Clinical Outcomes.
    Garrouste C; Canaud G; Büchler M; Rivalan J; Colosio C; Martinez F; Aniort J; Dudreuilh C; Pereira B; Caillard S; Philipponnet C; Anglicheau D; Heng AE
    Transplantation; 2017 Mar; 101(3):649-656. PubMed ID: 27043407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LDL-apheresis-induced remission of focal segmental glomerulosclerosis recurrence in pediatric renal transplant recipients.
    Shah L; Hooper DK; Okamura D; Wallace D; Moodalbail D; Gluck C; Koziell A; Zaritsky JJ
    Pediatr Nephrol; 2019 Nov; 34(11):2343-2350. PubMed ID: 31250206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Immunosuppressive Therapy in Primary Focal Segmental Glomerulosclerosis: A Systematic Review and Meta-analysis.
    Caster DJ; Magalhaes B; Pennese N; Zaffalon A; Faiella M; Campbell KN; Radhakrishnan J; Tesar V; Trachtman H
    Kidney Med; 2022 Aug; 4(8):100501. PubMed ID: 36032548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose methylprednisolone pulse therapy in Chinese children with steroid resistant focal segmental glomerulosclerosis.
    Chang JW; Yang LY; Wang HH
    Pediatr Int; 2007 Jun; 49(3):349-54. PubMed ID: 17532834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety.
    Campbell KN; Gesualdo L; Murphy E; Rheault MN; Srivastava T; Tesar V; Komers R; Trachtman H
    Kidney Med; 2024 Jun; 6(6):100833. PubMed ID: 38831932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis.
    Siligato R; Cernaro V; Nardi C; De Gregorio F; Gembillo G; Costantino G; Conti G; Buemi M; Santoro D
    Expert Opin Investig Drugs; 2018 Nov; 27(11):839-879. PubMed ID: 30360670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of adalimumab in pediatric patients with Crohn disease.
    Wyneski MJ; Green A; Kay M; Wyllie R; Mahajan L
    J Pediatr Gastroenterol Nutr; 2008 Jul; 47(1):19-25. PubMed ID: 18607264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is CD44 in glomerular parietal epithelial cells a pathological marker of renal function deterioration in primary focal segmental glomerulosclerosis?
    Froes BP; de Almeida Araújo S; Bambirra EA; Oliveira EA; Simões E Silva AC; Pinheiro SVB
    Pediatr Nephrol; 2017 Nov; 32(11):2165-2169. PubMed ID: 28799058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T Lymphocyte Activation Markers as Predictors of Responsiveness to Rituximab among Patients with FSGS.
    Chan CY; Liu ID; Resontoc LP; Ng KH; Chan YH; Lau PY; Than M; Jordan SC; Lam KP; Yeo WS; Yap HK
    Clin J Am Soc Nephrol; 2016 Aug; 11(8):1360-1368. PubMed ID: 27269610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated asymmetric dimethylarginine (ADMA) and inverse correlation between circulating ADMA and glomerular filtration rate in children with sporadic focal segmental glomerulosclerosis (FSGS).
    Lücke T; Kanzelmeyer N; Chobanyan K; Tsikas D; Franke D; Kemper MJ; Ehrich JH; Das AM
    Nephrol Dial Transplant; 2008 Feb; 23(2):734-40. PubMed ID: 18175783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective study of collapsing focal segmental glomerulosclerosis.
    Raja R; Nada R; Yadav AK; Kumar A; Goyal A; Kumar V; Rathi M; Kohli HS; Gupta KL; Sakhuja V; Jha V
    Ren Fail; 2016 Jul; 38(6):894-8. PubMed ID: 27266801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity.
    Cho ME; Hurley JK; Kopp JB
    Am J Kidney Dis; 2007 Feb; 49(2):310-7. PubMed ID: 17261434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical course of primary focal segmental glomerulosclerosis (FSGS) in Turkish children: a report from the Turkish Pediatric Nephrology FSGS Study Group.
    Beşbaş N; Ozaltin F; Emre S; Anarat A; Alpay H; Bakkaloğlu A; Baskin E; Buyan N; Dönmez O; Düşünsel R; Ekim M; Göko F; Gür-Güven A; Kavukçu S; Mir S; Sönmez F
    Turk J Pediatr; 2010; 52(3):255-61. PubMed ID: 20718182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.